Amorphous Suvorexant Dispersion for Solubility and Bioavailability

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing formulations of suvorexant, an orexin receptor antagonist, face challenges in achieving optimal bioavailability and solubility, which affects its therapeutic efficacy.

Innovation Solution

A pharmaceutical composition comprising suvorexant, a concentration-enhancing polymer, and optionally a surfactant, where the polymer forms an amorphous dispersion with suvorexant to increase solubility and bioavailability, using polymers such as polyvinylpyrrolidinone and hydroxypropyl methyl cellulose acetate succinate to create a stable, amorphous form.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If conventional formulations of suvorexant are used, then manufacturing is simpler, but solubility and bioavailability are insufficient

Engineering Contradiction:

ImprovesolubilityVSAvoidformulation complexity

Core Design Contradiction:

Quantity of substanceVSDevice complexity

Solution Approach 1:

The patent changes the physical state of suvorexant from crystalline to amorphous form, fundamentally altering its dissolution properties. This parameter change enables significantly improved solubility and bioavailability without requiring complex formulation strategies, directly resolving the technical contradiction between solubility enhancement and formulation simplicity.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent creates a composite material system by combining amorphous suvorexant with specific excipients and polymers in a hot melt extrusion process. This composite approach maintains manufacturing simplicity while achieving superior solubility characteristics, as the amorphous state of suvorexant within the composite matrix provides enhanced dissolution without complicating the overall formulation process.

Inventive Principle:

Principle #40Composite materials

2Reliability

If crystalline form of suvorexant is used, then formulation is more stable, but bioavailability is reduced

Engineering Contradiction:

Improveformulation stabilityVSAvoidbioavailability

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The patent applies parameter change by transforming suvorexant from its stable crystalline state to an amorphous state during hot melt extrusion. Although amorphous forms are generally less stable, the controlled processing conditions and specific formulation composition maintain adequate stability while dramatically improving bioavailability, thus resolving the contradiction between stability and bioavailability.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent introduces specific excipients and polymers as intermediaries that stabilize the amorphous suvorexant during storage and processing. These intermediary substances prevent premature crystallization and degradation, enabling the formulation to maintain both the bioavailability advantages of the amorphous state and the stability requirements for pharmaceutical products.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Quantity of substance

If amorphous dispersion is created with polymer, then solubility increases, but manufacturing process becomes more complex

Engineering Contradiction:

ImprovesolubilityVSAvoidmanufacturing ease

Core Design Contradiction:

Quantity of substanceVSEase of manufacture

Solution Approach 1:

The patent replaces complex mechanical mixing and dissolution processes with a hot melt extrusion approach. By melting the polymer and suvorexant together and then cooling them, the amorphous dispersion is created through thermal processing rather than mechanical force, simplifying the manufacturing process while achieving the desired solubility enhancement.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent utilizes phase transitions of the polymer and suvorexant during hot melt extrusion. By heating above the melting point to create a homogeneous melt and then cooling to form the amorphous dispersion, the process leverages natural phase changes to achieve mixing and dispersion without complex equipment or procedures, maintaining manufacturing ease while improving solubility.

Inventive Principle:

Principle #36Phase transitions

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The amorphous dispersion enhances suvorexant's solubility and bioavailability, leading to improved therapeutic effects and reduced variability in response among subjects.

Implementation Method 1

the polymer forms an amorphous dispersion with suvorexant to increase solubility and bioavailability

Methodology Applied

Scientific EffectAmorphous dispersion:

Data Source

PatentUS12599610B2Solid dosage formulations of an orexin receptor antagonist

Publication Date: 2026.04.14 MERCK SHARP & DOHME LLC

AI summary

The present invention is directed to a pharmaceutical composition comprising the compound suvorexant, or a pharmaceutically acceptable salt thereof, a concentration-enhancing polymer, and optionally a pharmaceutically acceptable surfactant.